S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:AEZSAEterna Zentaris Stock Price, Forecast & News

$0.50
-0.02 (-3.98 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.49
Now: $0.50
$0.53
50-Day Range
$0.38
MA: $0.55
$0.92
52-Week Range
$0.37
Now: $0.50
$2.57
Volume6.00 million shs
Average Volume1.84 million shs
Market Capitalization$20.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. It also has a collaboration agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for the development, manufacture, and commercialization of Zoptrex, which has completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer in the People's Republic of China. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.
Read More
AEterna Zentaris logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AEZS
CUSIPN/A
Phone49-6942-6020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$530,000.00
Book Value$0.02 per share

Profitability

Net Income$-6,040,000.00
Net Margins-274.71%

Miscellaneous

EmployeesN/A
Market Cap$20.74 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$0.50
-0.02 (-3.98 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AEZS News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions

How has AEterna Zentaris' stock been impacted by Coronavirus (COVID-19)?

AEterna Zentaris' stock was trading at $0.6795 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AEZS stock has decreased by 25.8% and is now trading at $0.5043.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AEterna Zentaris?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AEterna Zentaris in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AEterna Zentaris
.

When is AEterna Zentaris' next earnings date?

AEterna Zentaris is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for AEterna Zentaris
.

How were AEterna Zentaris' earnings last quarter?

AEterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.04. The biopharmaceutical company earned $0.07 million during the quarter.
View AEterna Zentaris' earnings history
.

What are Wall Street analysts saying about AEterna Zentaris stock?

Here are some recent quotes from research analysts about AEterna Zentaris stock:
  • 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (11/5/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating of AEZS and our 12-month price target of $5.50 per share. We derive our price target using a risk- adjusted net present value analysis of potential US and EU royalties, discounted at 18%, to reach a total rNPV of $66M for the royalty streams." (8/15/2019)

Has AEterna Zentaris been receiving favorable news coverage?

Media coverage about AEZS stock has been trending extremely negative on Thursday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AEterna Zentaris earned a news sentiment score of -4.1 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.
View the latest news about AEterna Zentaris
.

Are investors shorting AEterna Zentaris?

AEterna Zentaris saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 164,500 shares, an increase of 192.7% from the June 15th total of 56,200 shares. Based on an average trading volume of 1,950,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.7% of the shares of the company are sold short.
View AEterna Zentaris' Short Interest
.

Who are some of AEterna Zentaris' key competitors?

What other stocks do shareholders of AEterna Zentaris own?

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the following people:
  • Mr. Michael V. Ward, Pres & CEO (Age 62)
  • Ms. Leslie Auld, Sr. VP & CFO
  • Mr. Brian Garrison, Sr. VP of Global Corp. Operations & Corp. Devel.
  • Dr. Nicola Ammer, Chief Medical Officer & VP of Clinical Devel.
  • Mr. Olaf Althaus, GM & MD

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

Who are AEterna Zentaris' major shareholders?

AEterna Zentaris' stock is owned by many different institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.12%).

Which major investors are buying AEterna Zentaris stock?

AEZS stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC.

How do I buy shares of AEterna Zentaris?

Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $0.50.

How big of a company is AEterna Zentaris?

AEterna Zentaris has a market capitalization of $20.74 million and generates $530,000.00 in revenue each year.

What is AEterna Zentaris' official website?

The official website for AEterna Zentaris is www.zentaris.com.

How can I contact AEterna Zentaris?

AEterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 49-6942-6020 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.